West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$299.81 USD
+0.01 (0.00%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $299.98 +0.17 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Buy These 5 Low Leverage Stocks to Weather Coronavirus Impact
by Aparajita Dutta
With the Q2 reporting cycle drawing to a close, investors must be eyeing stocks that exhibited solid earnings growth in the prior quarters. But choosing stocks with high debt level might be risky.
Allscripts' Collaboration to Advance Healthcare Innovation
by Zacks Equity Research
Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Ecolab's Synergex Sanitizer & Disinfectant Gets First EPA Nod
by Zacks Equity Research
Ecolab's (ECL) Synergex Santizer & Disinfectant becomes the first product to receive U.S. EPA for efficacy against biofilms.
McKesson Extends Partnership With CDC to Fight Coronavirus
by Zacks Equity Research
McKesson (MCK) extends partnership with the CDC to aid in the distribution of future COVID-19 vaccines.
Here's Why You Should Hold on to Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.
Baxter (BAX) Receives EUA for Regiocit Replacement Solution
by Zacks Equity Research
Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.
Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated
by Zacks Equity Research
Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
5 Top-Ranked Stocks Driving ETF as S&P 500 Nears New Highs
by Sweta Killa
Though most stocks in the fund's portfolio are in the green this year, we have highlighted five that are leading the way in the ETF and have a Zacks Rank #2, suggesting their continued outperformance.
Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.
National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat
by Zacks Equity Research
Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.
Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.
Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up
by Zacks Equity Research
Insulet's (PODD) total Omnipod product line comes up with record revenue growth.
Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.
Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.
Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.
NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.
ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.